SUMMARY
- EIT Pharma raised $35M in Series A funding.
- The funding will support FDA review and drug development.
- EIT Pharma develops treatments for infectious diseases.
Follow us
Follow usEIT Pharma, a Kirkland, WA-based biotechnology company focused on developing therapies for infectious diseases, has raised $35 million in a Series A funding round led by Propel Bio Partners.
The round also saw participation from Good Ventures, Arrowtown, and others.
The company will use the capital to advance FDA review activities for lonafarnib, prepare for manufacturing and commercial readiness, advance its infectious disease pipeline, and support corporate operations.
Funding Snapshot
| Metric | Details |
|---|---|
| Fundraise Amount | $35M |
| Funding Round | Series A |
| Lead Investor | Propel Bio Partners |
| Company | EIT Pharma |
| Sector | Biotechnology / Infectious Diseases |
| Headquarters | Kirkland, Washington, USA |
RECOMMENDED FOR YOU
[Funding alert] NYC-based Auxa Health Secures $5.2Million in Seed Funding
Devin Jacobs
Apr 23, 2024
About EIT Pharma
EIT Pharma is a biotechnology company developing therapies for infectious diseases with significant unmet medical needs. Its pipeline focuses on translating scientific innovation into potential treatments for serious diseases.
Read More:ACES Announce Strategic Partnership With Movandi
The infectious disease therapeutics market continues to see demand for new treatments as healthcare systems address serious diseases with limited or inadequate treatment options. Biotechnology companies are increasingly focused on therapies that can improve treatment accessibility, reduce treatment burden and address significant unmet medical needs.
Core offerings include:
- Infectious disease therapies
- Lonafarnib development
- Clinical and regulatory programs
- Patient-focused treatment solutions
Core Technologies / Products / Services
| Capability/Product | Application/Use Case |
|---|---|
| Lonafarnib | Investigational oral CHD therapy |
| Infectious disease pipeline | Development of treatments for serious infections |
| Oral drug delivery | Potentially improving treatment accessibility |
| Clinical development programs | Advancing therapies toward regulatory approval |
Leadership Comments
"This oversubscription of this round is a validation of EIT Pharma's founding belief that advancing important medicines is about recognizing unrealized potential and assembling the scientific, clinical, regulatory, and commercial expertise to turn that potential into a treatment for patients," said Dr. Leen Kawas, PhD, Chief Executive Officer of EIT Pharma.
"EIT Pharma pairs a differentiated, late-stage asset with a team experienced in moving complex programs through development and regulatory review," said Richard Kayne, General Partner of Propel Bio Partners. "We see meaningful value potential across EIT Pharma's infectious disease pipeline, and we're backing a management team with the scientific, clinical, and commercial discipline to realize it.
Read More:Tim Cook Steps Down as Apple Chief Executive Officer
Recommended Stories for You
Team SR Aug 20, 2024
Devin Jacobs Jul 2, 2026
Startuprise Feb 11, 2026
Devin Jacobs Feb 5, 2024
Devin Jacobs May 25, 2024
Devin Jacobs Feb 29, 2024
Trending Stories
Speakeasy Scores $8.8M in funding from Positive Sum to Scale Operations for Live Experiences
[Funding alert] NYC-based Qortex Secures $10m in Funding
Ken Bertsch Joins Anteris Advisors as Senior Advisor
HealthTree Foundation Appoints Lisa Gray to Its Board of Directors
Defense-Based K2 Space Raises $500M in Series D Funding Round
AI Startup Petra Labs Raises $5.2M in Seed Funding Round
AI Startup Lemma Raises $2.3M in Pre-Seed Round
Gunderson Dettmer Welcomes Kate Cusick as Chief Communications Officer
